41,157 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 41,157 shares of the company’s stock, valued at approximately $1,478,000.

Several other institutional investors have also recently bought and sold shares of DYN. Seven Eight Capital LP raised its position in Dyne Therapeutics by 195.7% during the 2nd quarter. Seven Eight Capital LP now owns 53,739 shares of the company’s stock worth $1,896,000 after purchasing an additional 35,568 shares during the last quarter. State of New Jersey Common Pension Fund D bought a new stake in Dyne Therapeutics during the 3rd quarter valued at $1,588,000. Jennison Associates LLC raised its holdings in shares of Dyne Therapeutics by 1.5% in the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock worth $48,383,000 after acquiring an additional 19,730 shares during the last quarter. Mutual of America Capital Management LLC purchased a new stake in shares of Dyne Therapeutics in the second quarter worth approximately $1,724,000. Finally, Vanguard Group Inc. lifted its stake in Dyne Therapeutics by 47.7% during the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after acquiring an additional 1,110,629 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on DYN. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Guggenheim raised their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. Morgan Stanley lifted their target price on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus boosted their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, Piper Sandler reissued an “overweight” rating and issued a $53.00 price target on shares of Dyne Therapeutics in a report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.82.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN opened at $29.23 on Wednesday. The company has a market cap of $2.97 billion, a P/E ratio of -8.21 and a beta of 1.10. Dyne Therapeutics, Inc. has a 52-week low of $10.12 and a 52-week high of $47.45. The firm’s fifty day moving average is $32.06 and its two-hundred day moving average is $35.40.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, CEO John Cox acquired 32,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. The trade was a -133.33 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now owns 234,127 shares of the company’s stock, valued at $8,533,929.15. This trade represents a 25.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 176,257 shares of company stock valued at $6,193,718 in the last three months. Company insiders own 20.77% of the company’s stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.